Christopher Lloyd
Director AstraZeneca
Chris is a Director and Group Lead within Biologics Engineering (BE) at AstraZeneca, based in Cambridge, UK, working on the development of highly innovative antibody-based modalities for the treatment of cancer. He has over 20 years’ experience in the field of antibody engineering and protein biophysics, across multiple therapeutic areas and contributing to various drug programs in clinical development. He is currently responsible for leading the immune cell engager technology platform development and oversees early-stage research projects within BE for the Immune-Oncology therapy area.
Seminars
Monday 8th June 2026
Unlocking Safe & Potent T-Cell Engagers by Applying Rational Design Principles to Maximise Efficacy & Minimise Toxicity
1:30 pm
- Tuning affinity, valency, and synapse engagement to optimise efficacy while maintaining safety
- Engineering CD8 T-cell selectivity to minimise CRS and ICANS without compromising therapeutic potency
- Presenting pre-clinical data on leading programs entering clinical trials
Thursday 9th July 2026
Chair’s Opening Remarks
8:50 am
Thursday 9th July 2026
Chair’s Closing Remarks
4:40 pm
